VACCINE USAGE: VAQTA is a vaccine indicated for the prevention of disease caused by hepatitis A virus (HAV) in persons 12 months of age and older. The primary dose should be given at least 2 weeks prior to expected exposure to HAV.
VACCINE DOSAGE: Children/Adolescents: vaccination consists of a 0.5-mL primary dose administered intramuscularly, and a 0.5-mL booster dose administered intramuscularly 6 to 18 months later. Adults: vaccination consists of a 1-mL primary dose administered intramuscularly, and a 1-mL booster dose administered intramuscularly 6 to 18 months later.
VACCINE INGEDIENTS: amorphous aluminum hydroxyphosphate sulfate, bovine albumin, formaldehyde, neomycin, sodium borate, MRC-5 (human diploid) cells.
ADVERSE VACCINE REACTIONS: constipation, vomiting, injection-site bruising, injection-site ecchymosis
Otitis media, nasopharyngitis, rhinitis, viral infection, croup, pharyngitis streptococcal, anorexia, insomnia, crying, laryngotracheobronchitis, viral exanthema, gastroenteritis viral roseola, cough, nasal congestion, respiratory congestion, rash vesicular, measles-like/rubella-like rash, varicellalike rash, rash morbilliform.